Trial Profile
An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors Teva Branded Pharmaceutical Products R&D
- 20 Mar 2019 New trial record